A new trastuzumab (Herceptin) biosimilar has launched in India. Dr Reddy’s Laboratories, the developer of the biosimilar, indicated that the drug will be sold under the name Hervycta, and that it has been approved in India to treat HER2-postive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
A new trastuzumab (Herceptin) biosimilar has launched in India. Dr Reddy’s Laboratories, the developer of the biosimilar, indicated that the drug will be sold under the name Hervycta, and that it has been approved in India to treat HER2-postive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
“The launch of Hervycta will immensely benefit women in India who are suffering from HER2-positive breast cancer and are in need of access to high-quality, affordable, and innovative medicines,” said Raymond De Vré, senior vice president and head of biologics at Dr Reddy’s Laboratories, in a statement.
Biosimilar trastuzumab is Dr Reddy’s 4th biosimilar to be commercialized in India and in various other emerging markets. Other biosimilars developed by the company include darbepoetin alfa, sold as Cresp; filgrastim, sold as Grafeel; pegfilgrastim, sold as Peg-grafeel; and rituximab, sold as Reditux.
Herceptin sales in 2017 were reported as growing 5.7%, to $57 billion, beating the expectations of analysts. In the European Union, there are currently 3 trastuzumab biosimilars on the market, sold as Ontruzant, Herzuma, and Kanjinti. Although the United States has approved 1 trastuzumab biosimilar, Ogivri, it has yet to reach the market.
In India, while regulatory standards differ from those in the United States, the biosimilar space is comparatively well-established. According to Generics and Biosimilars Initiative (GaBI), the first “similar biologic” was approved and marketed in India in 2000, or 15 years before the first approval in the United States. Drug makers in India are motivated in part by the government’s initiative to offer subsidies to biosimilar manufacturers. In 2017, an analysis conducted by Decision Resources Group (DRG) found that more than 40 biosimilars were in clinical development in India, far more than are currently being developed in the United States.
The Indian market also sees faster approvals and shorter review periods than other regulatory districts due to factors such as high discounting and reduced patent protections for innovator drugs.
“We strive every day to do what matters most for our patients. Hervycta is a step forward in our effort to accelerate access to cancer patients in India, in the oncology biosimilar space,” said MV Ramana, the CEO of branded markets at Dr. Reddy’s laboratories.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.